الفهرس 
REVIEWOnly 14 pages are availabe for public view
 |  | from | 16 |  |  |
| | | from | 16 | | |
Abstract
An effective and safe oral anticoagulant that needs no monitoring for dose adjustment is urgently needed for the treatment of diseases that require long-term anticoagulation, currently available anticoagulants have well-known limitations. Low-molecular-weight heparins require subcutaneous administration. Vitamin K antagonists (VKAs) are orally active but require laboratory monitoring for dose initiation and adjustment, have a narrow therapeutic window, and are subject to drug and food interactions. An orally active, safe, and effective anticoagulant that requires no monitoring for dose adjustment would have the potential to radically simplify the management of thromboembolic disorders.
Patients were fully diagnosed according to Well’s Scoring System (Well’s et al., 2003) for DVT diagnosis at outpatient clinic accompanied with duplex for venous system of the affected lower limb and assessment of the degree of lower limb edema, pain and claudication.
Our study results shows non-significant difference in results between oral anti factor Xa technique and the L.M.W.H. & V.K.A technique in treatment of acute stage of D.V.T, but the oral anti factor 10 (rivaroxaban) have an upper hand in being orally taken and needs less monitoring of coagulation profile.